08. December 2023

ARQIS has advised global private equity healthcare specialist ARCHIMED on the acquisition of Germany-based full-service Contract Research Organization (CRO) Proinnovera. The purchase built the platform for the further acquisition of US-based CRO Symbio (for ARCHIMED advised by White & Case) and the successful merger of the two companies.

Proinnovera and Symbio are offering cost saving, time-efficient outsourced services for dermatological therapy formulation and clinical trial testing. The merged group, Symbio Proinnovera, provides consulting, testing and clinical research through every development stage, from conception to global regulatory approval and commercialization. Symbio Proinnovera aims to contribute to shorter trials and lower costs for clients (ultimately giving the public faster and cheaper access to innovative drugs) using its extensive dermatological testing database. Acquisitions should further accelerate company growth.

The ARQIS team led by partner Dr Jörn-Christian Schulze has been advising ARCHIMED for many years, most recently on the acquisition of the ZytoMax Group. Schulze's team has many years of successful experience, particularly in the healthcare and technology sector.

Advisors to ARCHIMED for the acquisition of Proinnovera

ARQIS (Dusseldorf): Dr. Jörn-Christian Schulze ARQIS (Düsseldorf): Dr. Jörn-Christian Schulze (Lead), Christos Choudeloudis (both Private Equity); Partner: Dr. Ulrich Lienhard (Real Estate), Tobias Neufeld (Data Law), Dr. Astrid Seehafer (Product Law); Counsel: Sina Janke (Compliance), Jens Knipping (Tax), Anja Mehrtens (Labour Law); Managing Associates: Dr. Hanna Caesar (Labour Law), Kamil Flak (Private Equity), Nora Stratmann (IP); Associates: Tim Bresemann (Real Estate), Jasmin Grünen (Private Equity/Tax), Thomas Lipsky (IP), Katrin Ludwig (Private Equity), Eva Ritte (Product Law), Daniel Schlemann (Data Law), Severin Steffens (Private Equity), Dr. Hendrik Völkerding (Labour Law); Legal Specialist: Qing Xia (Private Equity)